نتائج البحث - "Simone M. Goldinger"

1

Long-Term Response to Intermittent Binimetinib in Patients with NRAS-Mutant Melanoma

المؤلفون: Alexandra Valeska Matter, Simone M. Goldinger, Sara Micaletto, Ursula Urner-Bloch, Reinhard Dummer

المساهمون: University of Zurich, Dummer, Reinhard

المصدر: The Oncologist

مصطلحات موضوعية: Male, Proto-Oncogene Proteins B-raf, 0301 basic medicine, Neuroblastoma RAS viral oncogene homolog, MAPK/ERK pathway, Cancer Research, Skin Neoplasms, medicine.medical_treatment, 610 Medicine & health, Drug resistance, GTP Phosphohydrolases, Targeted therapy, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Immune system, Cell Line, Tumor, Humans, Medicine, 1306 Cancer Research, Melanoma, Protein Kinase Inhibitors, Aged, business.industry, Kinase, 10177 Dermatology Clinic, Membrane Proteins, Binimetinib, medicine.disease, 030104 developmental biology, Oncology, chemistry, 030220 oncology & carcinogenesis, Mutation, Cancer research, 2730 Oncology, Precision Medicine Clinic: Molecular Tumor Board, Benzimidazoles, Female, business

وصف الملف: 855_Matter_A._et_al._Long-Term_response_to_intermittent_binimetinib_in_patients_with_NRAS-mutant_Melanoma_the_Oncologist_2020.pdf - application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::145601bc949f4b0f83188d4b388aa2acTest
https://doi.org/10.1634/theoncologist.2019-0656Test

2

A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis

المصدر: Nature Medicine. 25:1243-1250

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::c627227be1cd83e714203554c40967a9Test
https://doi.org/10.1038/s41591-019-0523-2Test

3

Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti‐PD‐1 antibodies

المصدر: Pigment Cell Melanoma Res

مصطلحات موضوعية: Male, 0301 basic medicine, medicine.medical_specialty, Bevacizumab, medicine.medical_treatment, Programmed Cell Death 1 Receptor, Ipilimumab, Dermatology, Antibodies, Article, General Biochemistry, Genetics and Molecular Biology, Cohort Studies, Necrosis, 03 medical and health sciences, 0302 clinical medicine, Risk Factors, medicine, Humans, Cumulative incidence, Radiation Injuries, Melanoma, business.industry, Incidence, Incidence (epidemiology), Brain, Middle Aged, medicine.disease, Magnetic Resonance Imaging, Survival Analysis, Radiation therapy, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Multivariate Analysis, Cohort, Female, Neurosurgery, Radiology, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04f18946bddd2aec8b60a7eecf640116Test
https://doi.org/10.1111/pcmr.12775Test

4

Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter study

المؤلفون: Reinhard Dummer, Valerie C Amann, Anita Giobbie-Hurder, Simone M. Goldinger, Donald P. Lawrence, Lisa Zimmer, Joanna Mangana, Elisabeth Livingstone, Joshua Z. Drago, Tianqi Chen, Alfred Zippelius, Marco Siano, Ryan J. Sullivan

المصدر: Melanoma Research. 29:65-69

مصطلحات موضوعية: Adult, Male, Proto-Oncogene Proteins B-raf, 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Adolescent, Pyridones, MAP Kinase Kinase 1, Pyrimidinones, Dermatology, Nodular melanoma, Young Adult, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Oximes, Biomarkers, Tumor, medicine, Humans, Vemurafenib, Melanoma, Protein Kinase Inhibitors, Survival rate, Aged, Retrospective Studies, Trametinib, Cobimetinib, Brain Neoplasms, business.industry, Imidazoles, Dabrafenib, Binimetinib, Middle Aged, Prognosis, medicine.disease, Survival Rate, 030104 developmental biology, chemistry, 030220 oncology & carcinogenesis, Female, business, Follow-Up Studies, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7123c6e5c10387b054ed15296746eab0Test
https://doi.org/10.1097/cmr.0000000000000527Test

5

Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma

المؤلفون: Nadia Plantier, Sabrina A. Hogan, Simone M. Goldinger, Marieke I.G. Raaijmakers, Anais Courtier, Jean-François Mouret, Thi Dan Linh Nguyen-Kim, Phil F. Cheng, John B. A. G. Haanen, Mitchell P. Levesque, Solène Perez, Pia Kvistborg, Reinhard Dummer, Nicoletta F Jaberg-Bentele, Manuarii Manuel, Nicolas Pasqual

المساهمون: University of Zurich, Levesque, Mitchell P

المصدر: Cancer Immunology Research

مصطلحات موضوعية: Adult, Male, 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Skin Neoplasms, medicine.medical_treatment, Programmed Cell Death 1 Receptor, Immunology, Receptors, Antigen, T-Cell, 610 Medicine & health, chemical and pharmacologic phenomena, Antibodies, Monoclonal, Humanized, Peripheral blood mononuclear cell, 03 medical and health sciences, symbols.namesake, Antineoplastic Agents, Immunological, 0302 clinical medicine, Internal medicine, medicine, Humans, CTLA-4 Antigen, 1306 Cancer Research, Progression-free survival, Melanoma, Fisher's exact test, Aged, 2403 Immunology, Receiver operating characteristic, 10042 Clinic for Diagnostic and Interventional Radiology, business.industry, T-cell receptor, 10177 Dermatology Clinic, Immunotherapy, Middle Aged, medicine.disease, Ipilimumab, Progression-Free Survival, 3. Good health, 030104 developmental biology, 030220 oncology & carcinogenesis, Monoclonal, symbols, Female, business

وصف الملف: Peripheral_blood_TCR_repertoire_profiling_may_facilitate.pdf - application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2183a0c56e9ee4715bc5ea53f32f0b44Test
https://doi.org/10.1158/2326-6066.cir-18-0136Test

6

Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition

المصدر: European journal of cancer (Oxford, England : 1990). 148

مصطلحات موضوعية: 0301 basic medicine, Male, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, Programmed Cell Death 1 Receptor, Medizin, Gastroenterology, Targeted therapy, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Prospective cohort study, Immune Checkpoint Inhibitors, Melanoma, Aged, Retrospective Studies, business.industry, Confounding, Retrospective cohort study, Middle Aged, medicine.disease, Prognosis, Immune checkpoint, 3. Good health, Blockade, Survival Rate, 030104 developmental biology, Oncology, CTLA-4, 030220 oncology & carcinogenesis, Drug Therapy, Combination, Female, Immunotherapy, business, Follow-Up Studies

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a7b5b295efc1524ab0bf2996f38c02fTest
https://pubmed.ncbi.nlm.nih.gov/33735811Test

7

Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients

المصدر: British Journal of Cancer

مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Cancer Research, Radiation-Sensitizing Agents, Skin Neoplasms, medicine.medical_treatment, Medizin, Cohort Studies, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, Oximes, Vemurafenib, Prospective cohort study, Melanoma, Aged, 80 and over, Imidazoles, Middle Aged, Treatment Outcome, 030220 oncology & carcinogenesis, Female, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Adolescent, Drug Administration Schedule, BRAF, 03 medical and health sciences, Young Adult, Internal medicine, medicine, Humans, ddc:610, dabrafenib, Protein Kinase Inhibitors, radiotherapy, Aged, Retrospective Studies, business.industry, Dabrafenib, Retrospective cohort study, medicine.disease, Radiation therapy, radiation, 030104 developmental biology, Concomitant, Clinical Study, Skin cancer, business

وصف الملف: application/octet-stream

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1e8f1dc9f3855c01558c2eeec19ddedTest
http://europepmc.org/articles/PMC5886123Test

8

Does the distribution pattern of brain metastases during BRAF inhibitor therapy reflect phenotype switching?

المؤلفون: Silvia A. Haueis, Ralph P. Braun, Mitchell P. Levesque, Simone M. Goldinger, Mirjana Urosevic-Maiwald, Joanna Mangana, Phil F. Cheng, Pascale Kränzlin, Reinhard Dummer

المساهمون: University of Zurich, Goldinger, Simone M

المصدر: Melanoma Research. 27:231-237

مصطلحات موضوعية: Male, 0301 basic medicine, Oncology, Cancer Research, Pathology, BRAF inhibitor, medicine.medical_treatment, Targeted therapy, 0302 clinical medicine, Modified recist, 1306 Cancer Research, Melanoma, Aged, 80 and over, Brain Neoplasms, 10177 Dermatology Clinic, Neoplasms, Second Primary, Middle Aged, Prognosis, Phenotype, Survival Rate, 030220 oncology & carcinogenesis, Distribution pattern, Disease Progression, 2730 Oncology, Female, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, 610 Medicine & health, Dermatology, 2708 Dermatology, Young Adult, 03 medical and health sciences, Text mining, Internal medicine, medicine, Humans, Neoplasm Invasiveness, In patient, Protein Kinase Inhibitors, Aged, Retrospective Studies, business.industry, medicine.disease, 030104 developmental biology, Case-Control Studies, business, Follow-Up Studies

وصف الملف: 684_Haueis_S._et_al._Does_the_distribution_pattern_of_brain_metastases_during_BRAF_Melanoma_Res._2017.pdf - application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d8487ec9a6452542b2955e97293575dTest
https://doi.org/10.1097/cmr.0000000000000338Test

9

Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC

المصدر: Cancer immunology research, vol 5, iss 5

مصطلحات موضوعية: Male, 0301 basic medicine, Oncology, Cancer Research, Pathology, Lung Neoplasms, Programmed Cell Death 1 Receptor, Kaplan-Meier Estimate, Pembrolizumab, CD8-Positive T-Lymphocytes, Metastasis, Antineoplastic Agents, Immunological, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, Monoclonal, 80 and over, Medicine, Lymphocytes, Non-Small-Cell Lung, Melanoma, Humanized, Lung, Cancer, Aged, 80 and over, biology, Liver Disease, Liver Neoplasms, Lung Cancer, Pharmacology and Pharmaceutical Sciences, Middle Aged, Treatment Outcome, Immunological, 030220 oncology & carcinogenesis, Cohort, Female, Antibody, Adult, medicine.medical_specialty, Oncology and Carcinogenesis, Immunology, Antineoplastic Agents, Antibodies, Monoclonal, Humanized, Article, Disease-Free Survival, Antibodies, Young Adult, 03 medical and health sciences, Lymphocytes, Tumor-Infiltrating, Clinical Research, Internal medicine, Carcinoma, Humans, Tumor-Infiltrating, Lung cancer, Aged, business.industry, medicine.disease, 030104 developmental biology, biology.protein, Digestive Diseases, business

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e6e83e1062cd8697d5a6ca0e4709a53Test
https://doi.org/10.1158/2326-6066.cir-16-0325Test

10

Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity:clinical outcomes in advanced melanoma

المساهمون: Surgery, Faculty of Medicine and Pharmacy, Clinical sciences, Medical Oncology, Laboratory for Medical and Molecular Oncology, Laboratory of Molecullar and Cellular Therapy, HUS Comprehensive Cancer Center, Department of Oncology, University of Helsinki, University of Zurich, Jansen, Y J L

المصدر: Jansen, Y J L, Rozeman, E A, Mason, R, Goldinger, S M, Geukes Foppen, M H, Højberg, L, Schmidt, H, van Thienen, J V, Haanen, J B A G, Tiainen, L, Svane, I M, Mäkelä, S, Seremet, T, Arance, A, Dummer, R, Bastholt, L, Nyakas, M, Straume, O, Menzies, A M, Long, G V, Atkinson, V, Blank, C U & Neyns, B 2019, ' Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity : clinical outcomes in advanced melanoma ', Annals of Oncology, vol. 30, no. 7, pp. 1154-1161 . https://doi.org/10.1093/annonc/mdz110Test
Jansen, Y J L, Rozeman, E A, Mason, R, Goldinger, S M, Geukes Foppen, M H, Hoejberg, L, Schmidt, H, Van Thienen, J V, Haanen, J B A G, Tiainen, L, Svane, I M, Mäkelä, S, Seremet, T, Arance, A, Dummer, R, Bastholt, L, Nyakas, M, Straume, O, Menzies, A M, Long, G V, Atkinson, V, Blank, C U & Neyns, B 2019, ' Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity : clinical outcomes in advanced melanoma ', Annals of Oncology, vol. 30, no. 7, mdz110, pp. 1154-1161 . https://doi.org/10.1093/annonc/mdz110Test
Jansen, Y J L, Rozeman, E A, Mason, R, Goldinger, S M, Geukes Foppen, M H, Hoejberg, L, Schmidt, H, Van Thienen, J V, Haanen, J B A G, Tiainen, L, Svane, I M, Mäkelä, S, Seremet, T, Arance, A, Dummer, R, Bastholt, L, Nyakas, M, Straume, O, Menzies, A M, Long, G V, Atkinson, V, Blank, C U & Neyns, B 2019, ' Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity : clinical outcomes in advanced melanoma ', Annals of Oncology, vol. 30, no. 7, pp. 1154-1161 . https://doi.org/10.1093/annonc/mdz110Test

مصطلحات موضوعية: Male, 0301 basic medicine, Skin Neoplasms, Programmed Cell Death 1 Receptor, 2720 Hematology, MONOTHERAPY, Pembrolizumab, Gastroenterology, Cohort Studies, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, Prospective Studies, Aged, 80 and over, anti-PD-1 therapy, 10177 Dermatology Clinic, Hematology, Middle Aged, Evaluable Disease, Prognosis, Substance Withdrawal Syndrome, 3. Good health, Survival Rate, Nivolumab, Oncology, SAFETY, 030220 oncology & carcinogenesis, Cohort, Disease Progression, SURVIVAL, Female, 2730 Oncology, immunotherapy, duration of treatment, Cohort study, medicine.drug, Adult, medicine.medical_specialty, 3122 Cancers, 610 Medicine & health, Ipilimumab, Antibodies, Monoclonal, Humanized, PROFILE, 03 medical and health sciences, Internal medicine, melanoma, medicine, Humans, PEMBROLIZUMAB, Aged, Retrospective Studies, business.industry, IPILIMUMAB, Discontinuation, Clinical trial, 030104 developmental biology, COMBINED NIVOLUMAB, business, Follow-Up Studies

وصف الملف: application/pdf; 811_Jansen_Y._et_al._Discontinuation_of_anti-PD-1_antibody_therapy_in_the_absence_of_disease_progression_or_treatment_limiting_toxicity_etc._Annals_of_Oncology_2019.pdf - application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::acb2426cfdad8323d67c5bd20e80a59eTest
https://curis.ku.dk/portal/da/publications/discontinuation-of-antipd1-antibody-therapy-in-the-absence-of-disease-progression-or-treatment-limiting-toxicityTest(00dd1bed-a3b3-45b5-b8d4-f911468c6499).html

تنقيح النتائج